Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Correction: Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review.","authors":"Roberto Rosenfeld, Stefano Sganga, Marco Badalamenti, Sveva Mortellaro, Marta Scorsetti, Ornella Garrone, Giovanni Maria Iannantuono, Elias Chandran, Michele Ghidini, Ciro Franzese","doi":"10.1007/s00432-025-06273-z","DOIUrl":"10.1007/s00432-025-06273-z","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 10","pages":"260"},"PeriodicalIF":2.8,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12440834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision medicine in liver transplantation for hepatocellular carcinoma: applications and prospects of third-generation sequencing technology.","authors":"Ye Tian, Xiaojuan Wang, Qian Lu","doi":"10.1007/s00432-025-06299-3","DOIUrl":"10.1007/s00432-025-06299-3","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Liver transplantation (LT) remains a vital treatment for HCC, yet it still faces numerous challenges in patient selection, recurrence monitoring, and personalized therapy. Third-generation sequencing (TGS), with its advantages of long read length, high throughput, direct detection of epigenetic modifications, real-time analysis and high accuracy, offers promise for advancing precision medicine in LT. While previous reviews have focused on TGS technical features, this review uniquely synthesizes its role in addressing specific clinical challenges in LT-HCC management and critically assesses its translational pathway. Specifically, it systematically examines TGS applications in candidate screening, recurrence monitoring, and personalized therapy for LT-HCC, analyzes its prospects for clinical translation, and aims to provide new insights for precise HCC treatment. We also discuss barriers to implementation and suggest solutions for integrating TGS into clinical workflows. This review provides a roadmap for leveraging TGS to revolutionize precision medicine in transplant hepatology.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"257"},"PeriodicalIF":2.8,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145053354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FBXW11 inhibits tumorigenesis by ubiquitinating YB1 in hepatocarcinoma.","authors":"Wuguang Liu, Bin Xu, Tong Wang, Xiaolong Liu, Chengyong Dong, Liming Wang","doi":"10.1007/s00432-025-06307-6","DOIUrl":"10.1007/s00432-025-06307-6","url":null,"abstract":"<p><strong>Purpose: </strong>The study aimed to investigate the role of FBXW11 in hepatocellular carcinoma (HCC) and its underlying mechanism. Specifically, we explored whether FBXW11 inhibits tumorigenesis by regulating YB1 ubiquitination and elucidated the functional significance of the FBXW11-YB1 axis in HCC progression.</p><p><strong>Methods: </strong>Clinical HCC specimens and cell lines (HCC-LM3, HuH7, Hep3B, SNU-449) were used. FBXW11 and YB1 expression were analyzed via Western blotting and immunohistochemistry (IHC). Gain- and loss-of-function assays (FBXW11 overexpression/knockdown) were performed to assess cell proliferation. Co-immunoprecipitation (Co-IP), mass spectrometry, and ubiquitination assays identified protein interactions and ubiquitination patterns. In vivo tumorigenesis was evaluated using xenograft models in nude mice. Correlations with clinicopathological features and survival were analyzed via statistical methods.</p><p><strong>Results: </strong>FBXW11 was significantly downregulated in HCC tissues, correlated with advanced TNM stages and poor overall survival (HR = 3.058, P = 0.042). FBXW11 overexpression suppressed HCC cell proliferation, while knockdown enhanced it. Mechanistically, FBXW11 directly interacted with the cold shock domain (CSD) of YB1, promoting K48-linked polyubiquitination and proteasomal degradation of YB1. YB1 overexpression rescued the tumor-suppressive effects of FBXW11 overexpression. In vivo, FBXW11 overexpression inhibited tumor growth by suppressing the YB1/Akt/mTOR signaling pathway, which was rescued by YB1 re-expression.</p><p><strong>Conclusion: </strong>FBXW11 acts as a tumor suppressor in HCC by mediating YB1 ubiquitination and degradation, thereby inhibiting the Akt/mTOR pathway. The FBXW11-YB1 axis represents a novel regulatory mechanism in hepatocarcinogenesis, highlighting FBXW11 as a potential prognostic biomarker and therapeutic target for HCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"256"},"PeriodicalIF":2.8,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145053622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular signatures of breast cancer in the Iranian population: a review of cell growth and cell cycle regulators.","authors":"Zeynab Mashayekh, Jalal Vallian Broojeni, Rasool Fatehi Fard, Sadeq Vallian","doi":"10.1007/s00432-025-06301-y","DOIUrl":"10.1007/s00432-025-06301-y","url":null,"abstract":"<p><p>The mortality rate of breast cancer remains relatively high in the Iranian population, with approximately 4810 deaths reported in 2020 (GLOBOCAN). This elevated fatality rate has been predominantly attributed to delays in diagnosis. In recent years, substantial research efforts have been directed toward elucidating cellular markers associated with breast cancer within this population. To this end, a systematic literature search was undertaken across both international and national databases, including PubMed, Scopus, IranMedex, and Magiran, covering the period from 2019 to 2024. The review synthesized data from studies encompassing a total of 15,318 Iranian breast cancer patients. The aggregated evidence provides comprehensive insights into cellular growth and cell cycle regulation markers implicated in breast cancer, thereby offering potential to inform the development of population-specific molecular diagnostic and prognostic strategies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"255"},"PeriodicalIF":2.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the transcription factor PATZ1 in tumorigenesis and metabolic regulation.","authors":"Yin Zheng, Jiabo Chen, Cheng Su","doi":"10.1007/s00432-025-06305-8","DOIUrl":"10.1007/s00432-025-06305-8","url":null,"abstract":"<p><p>PATZ1 (POZ/BTB and AT hook containing zinc finger 1) is an important member of the POZ/BTB (Poxvirus and Zinc finger / Broad-complex, Tramtrack, and Bric-à-brac) family and has been confirmed to be involved in the development and progression of various tumors. Moreover, differential expression of PATZ1 is associated with the prognosis of multiple cancers and systemic metabolic patterns. It participates in the regulation of oncogenes and a range of biological processes, including glucose and lipid metabolism. This review aims to summarize the current understanding of the relationship between the transcription factor PATZ1, tumorigenesis, and metabolism, with the goal of providing a theoretical basis for the development of PATZ1-targeted therapies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"254"},"PeriodicalIF":2.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolution of targeted intra operative radiotherapy in early breast cancer.","authors":"Aparimita Das, Khadeer Abdulkarim, Soirindhri Banerjee, Riya Kurmude, Joecelyn Kirani Tan, Lydia Prusty, Ishika Mahajan, Aruni Ghose, Aaditya Tiwari, Abbas Kassamali, Maryam Hasanova, Pratima Chapagain, Christian A Linares, Jayant S Vaidya, Stergios Boussios","doi":"10.1007/s00432-025-06294-8","DOIUrl":"10.1007/s00432-025-06294-8","url":null,"abstract":"<p><p>Targeted intraoperative radiotherapy (IORT) delivers a single dose of radiation to a fresh tumour bed immediately after lumpectomy, commonly used to treat early breast cancer (EBC). It is delivered during the same sitting, with improved patient compliance and better sparing of adjacent healthy tissue, compared to conventional adjuvant radiotherapy to the whole breast. The recently published 12-year results (median follow up of 8.6 years) of the TARGIT-A trial offers reliable conclusions, of comparable oncological outcomes with a reduced toxicity profile supporting IORT as a replacement for whole breast external beam radiotherapy (EBRT) for suitable patients with EBC. Reduced need of multiple hospital visits is an added logistic advantage which makes IORT a cost-effective, less painful and cosmetically favourable alternative to standard EBRT, now included in several international guidelines with growing popularity among clinicians worldwide.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"249"},"PeriodicalIF":2.8,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12423025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the catchment area of German comprehensive cancer centers by merging geographic healthcare data - an initiative of the ONCOnnect consortium.","authors":"A Kerscher, M Metzler, J Kapitza, L Bernhardt, K Dedner, M Krebs, C H Brandts","doi":"10.1007/s00432-025-06272-0","DOIUrl":"10.1007/s00432-025-06272-0","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"250"},"PeriodicalIF":2.8,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12422995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI-based radiomics signatures for predicting the efficacy of targeted therapy with lenvatinib in hepatocellular carcinoma: a retrospective cohort study.","authors":"Kun Huang, Haiyan Ma, Haikuan Liu, Jia Yuan, Xiaolan He, Yuancheng Liu, Zhouli Zheng, Rongpin Wang","doi":"10.1007/s00432-025-06306-7","DOIUrl":"10.1007/s00432-025-06306-7","url":null,"abstract":"<p><strong>Purpose: </strong>Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.</p><p><strong>Methods: </strong>This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients). Radiomics features were extracted using a Pyradiomics-based system. Biopsy specimens were used for immunohistochemical staining of epidermal growth factor receptor. Risk factors for predicting treatment response were screened out to construct models by logistic regression analysis. The performance of models was evaluated with receiver operating characteristic and decision curve analyses.</p><p><strong>Results: </strong>A total of 9370 radiomics features were extracted from five sequences. Subsequently, seven radiomics features were identified for modeling. Intratumoral vessel and expression level of epidermal growth factor receptor were independent risk factors for predicting treatment response to lenvatinib and were used to build a clinical model. No difference was found in predicting performance between clinical model and radiomics model. The combined model, integrating intratumoral vessel, epidermal growth factor receptor and radiomics features, had better predicting performance with areas under the receiver operating characteristic curve of 0.908, 0.877, and 0.870 for the training, internal test and external test sets, respectively.</p><p><strong>Conclusion: </strong>This study underscored the significant potential of radiomics features combined with clinicoradiological indicators in the prediction of treatment response to lenvatinib in patients with hepatocellular carcinoma.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"251"},"PeriodicalIF":2.8,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12422998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of comprehensive genomic profiling test for colorectal cancer: a single institution prospective observational study.","authors":"Hiroki Tanabe, Katsuyoshi Ando, Keitaro Takahashi, Tomomi Kamanaka, Sayaka Yuzawa, Junko Kikuchi, Yoshihito Ohhara, Shin Ariga, Tatsuya Shonaka, Chikayoshi Tani, Shin Otake, Takaaki Sasaki, Kenji Takahashi, Nobuhiro Ueno, Kentaro Moriichi, Mishie Tanino, Ichiro Kinoshita, Yusuke Mizukami, Mikihiro Fujiya","doi":"10.1007/s00432-025-06295-7","DOIUrl":"10.1007/s00432-025-06295-7","url":null,"abstract":"<p><strong>Purpose: </strong>Next-generation sequencing (NGS) has revolutionized cancer treatment by enabling comprehensive cancer genomic profiling (CGP) to guide genotype-directed therapies. While several prospective trials have demonstrated varying outcomes with CGP in patients with advanced solid tumors, its clinical utility in colorectal cancer (CRC) remains to be evaluated.</p><p><strong>Methods: </strong>We conducted a prospective observational study of CGP in our hospital between September 2019 and March 2024. Overall survival (OS) of the patients who received CGP-based therapy and those did not was compared, and genomic variables associated with OS were evaluated.</p><p><strong>Results: </strong>A total of 100 patients with CRC underwent CGP using four platforms. The median patient age was 67 years, and most had a good performance status. The most frequent genomic alterations were TP53 (82%), APC (82%), and KRAS (55%). Actionable mutations such as ERBB2 amplification and BRAF V600E were identified in some patients, and 9% received CGP-based therapy, including immune checkpoint inhibitors for tumor mutational burden-high or microsatellite instability-high tumors. Patients receiving CGP-based therapy had longer OS from expert panel discussion (16.0 vs. 10.8 months) compared to those who did not. Alterations in TP53, SMAD4, and NF1 were associated with worse OS. Interestingly, PTEN mutations were linked to improved survival. TP53 alterations were more common in left-sided CRC.</p><p><strong>Conclusion: </strong>Although some patients with CRC received CGP-guided therapy, a statistically significant survival benefit was not observed. However, TP53 and SMAD4 mutations were identified as negative prognostic markers, indicating their potential as targets for future drug development.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"253"},"PeriodicalIF":2.8,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12423004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The imitation game: large language models versus multidisciplinary tumor boards: benchmarking AI against 21 sarcoma centers from the ring trial.","authors":"Cheng-Peng Li, Aimé Terence Kalisa, Siyer Roohani, Kamal Hummedah, Franka Menge, Christoph Reißfelder, Markus Albertsmeier, Bernd Kasper, Jens Jakob, Cui Yang","doi":"10.1007/s00432-025-06304-9","DOIUrl":"10.1007/s00432-025-06304-9","url":null,"abstract":"<p><strong>Purpose: </strong>The study aims to compare the treatment recommendations generated by four leading large language models (LLMs) with those from 21 sarcoma centers' multidisciplinary tumor boards (MTBs) of the sarcoma ring trial in managing complex soft tissue sarcoma (STS) cases.</p><p><strong>Methods: </strong>We simulated STS-MTBs using four LLMs-Llama 3.2-vison: 90b, Claude 3.5 Sonnet, DeepSeek-R1, and OpenAI-o1 across five anonymized STS cases from the sarcoma ring trial. Each model was queried 21 times per case using a standardized prompt, and the responses were compared with human MTBs in terms of intra-model consistency, treatment recommendation alignment, alternative recommendations, and source citation.</p><p><strong>Results: </strong>LLMs demonstrated high inter-model and intra-model consistency in only 20% of cases, and their recommendations aligned with human consensus in only 20-60% of cases. The model with the highest concordance with the most common MTB recommendation, Claude 3.5 Sonnet, aligned with experts in only 60% of cases. Notably, the recommendations across MTBs were highly heterogenous, contextualizing the variable LLM performance. Discrepancies were particularly notable, where common human recommendations were often absent in LLM outputs. Additionally, the sources for the recommendation rationale of LLMs were clearly derived from the German S3 sarcoma guidelines in only 24.8% to 55.2% of the responses. LLMs occasionally suggested potentially harmful information were also observed in alternative recommendations.</p><p><strong>Conclusions: </strong>Despite the considerable heterogeneity observed in MTB recommendations, the significant discrepancies and potentially harmful recommendations highlight current AI tools' limitations, underscoring that referral to high-volume sarcoma centers remains essential for optimal patient care. At the same time, LLMs could serve as an excellent tool to prepare for MDT discussions.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 9","pages":"248"},"PeriodicalIF":2.8,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}